	US 12,319,938 B2
	Enhanced virus-like particles and methods of use thereof for delivery to cells
J. Keith Joung, Winchester, MA (US); and Peter Cabeceiras, Boston, MA (US)
Assigned to The General Hospital Corporation, Boston, MA (US); and President and Fellows of Harvard College, Cambridge, MA (US)
Filed by The General Hospital Corporation; and President and Fellows of Harvard College, Cambridge, MA (US)
Filed on Jan. 23, 2023, as Appl. No. 18/158,173.
Application 18/158,173 is a continuation of application No. PCT/US2021/043151, filed on Jul. 26, 2021.
Claims priority of provisional application 63/056,125, filed on Jul. 24, 2020.
Prior Publication US 2023/0227793 A1, Jul. 20, 2023
Int. Cl. C12N 7/00 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01)

CPC C12N 7/00 (2013.01) [C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 2310/20 (2017.05); C12N 2760/20223 (2013.01); C12N 2760/20252 (2013.01); C12N 2800/80 (2013.01)]

37 Claims

1. A particle for delivering a CRISPR-based genome editing protein to a nucleus of a target cell, the particle comprising:

(a) a membrane comprising a phospholipid bilayer with a glycoprotein on an external side; and

(b) a fusion protein comprising the CRISPR-based genome editing protein fused via a linker with a non-viral plasma membrane recruitment domain comprising a pleckstrin homology (PH) domain disposed in a core of the particle, and

wherein the fusion protein does not comprise a Gag protein.